BSE Live
Apr 09, 16:01Prev. Close
669.25
Open Price
680.55
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 09, 15:58Prev. Close
671.05
Open Price
675.05
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
725.80 (211)
| Key Financial Ratios of Albert David (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 33.59 | 15.62 | 17.24 | 27.96 | 84.10 | |
| Diluted EPS (Rs.) | 33.59 | 15.62 | 17.24 | 27.96 | 84.10 | |
| Cash EPS (Rs.) | 47.03 | 58.90 | 31.66 | 41.13 | 99.86 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 390.38 | 368.74 | 325.81 | 320.67 | 239.75 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 390.38 | 368.74 | 325.81 | 320.67 | 239.75 | |
| Dividend / Share(Rs.) | 7.00 | 6.00 | 5.50 | 5.50 | 5.50 | |
| Revenue from Operations/Share (Rs.) | 562.09 | 555.25 | 503.67 | 517.46 | 564.53 | |
| PBDIT/Share (Rs.) | 65.58 | 63.86 | 53.68 | 62.18 | 57.86 | |
| PBIT/Share (Rs.) | 52.13 | 51.63 | 39.25 | 49.01 | 42.09 | |
| PBT/Share (Rs.) | 50.73 | 50.55 | 37.75 | 47.72 | 110.42 | |
| Net Profit/Share (Rs.) | 33.59 | 46.68 | 17.24 | 27.96 | 84.10 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 11.66 | 11.50 | 10.65 | 12.01 | 10.24 | |
| PBIT Margin (%) | 9.27 | 9.29 | 7.79 | 9.47 | 7.45 | |
| PBT Margin (%) | 9.02 | 9.10 | 7.49 | 9.22 | 19.55 | |
| Net Profit Margin (%) | 5.97 | 8.40 | 3.42 | 5.40 | 14.89 | |
| Return on Networth / Equity (%) | 8.60 | 12.65 | 5.29 | 8.71 | 35.07 | |
| Return on Capital Employed (%) | 12.43 | 13.02 | 11.17 | 14.23 | 32.33 | |
| Return on Assets (%) | 5.98 | 9.01 | 3.40 | 5.60 | 21.44 | |
| Total Debt/Equity (X) | 0.01 | 0.00 | 0.15 | 0.16 | 0.15 | |
| Asset Turnover Ratio (%) | 100.18 | 107.27 | 99.40 | 103.79 | 143.93 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 2.48 | 2.69 | 1.94 | 1.86 | 2.01 | |
| Quick Ratio (X) | 1.95 | 2.06 | 1.45 | 1.29 | 1.37 | |
| Inventory Turnover Ratio (X) | 7.51 | 7.19 | 6.65 | 5.83 | 6.64 | |
| Dividend Payout Ratio (NP) (%) | 46.66 | 14.20 | 31.89 | 0.00 | 6.54 | |
| Dividend Payout Ratio (CP) (%) | 33.32 | 11.25 | 17.37 | 0.00 | 5.50 | |
| Earnings Retention Ratio (%) | 53.34 | 85.80 | 68.11 | 0.00 | 93.46 | |
| Cash Earnings Retention Ratio (%) | 66.68 | 88.75 | 82.63 | 0.00 | 94.50 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 178.32 | 218.18 | 209.97 | 197.10 | 167.59 | |
| EV/Net Operating Revenue (X) | 0.56 | 0.69 | 0.73 | 0.67 | 0.52 | |
| EV/EBITDA (X) | 4.76 | 5.99 | 6.85 | 5.55 | 5.08 | |
| MarketCap/Net Operating Revenue (X) | 0.57 | 0.71 | 0.72 | 0.62 | 0.53 | |
| Retention Ratios (%) | 53.33 | 85.79 | 68.10 | 0.00 | 93.45 | |
| Price/BV (X) | 0.82 | 1.07 | 1.12 | 0.99 | 1.25 | |
| Price/Net Operating Revenue | 0.57 | 0.71 | 0.72 | 0.62 | 0.53 | |
| Earnings Yield | 0.10 | 0.12 | 0.05 | 0.09 | 0.28 |
25.02.2026
Albert David Standalone December 2025 Net Sales at Rs 89.93 crore, up 8.24% Y-o-Y
13.11.2025
Albert David Standalone September 2025 Net Sales at Rs 87.24 crore, down 11.37% Y-o-Y
05.08.2025
Albert David Standalone June 2025 Net Sales at Rs 70.57 crore, down 21.03% Y-o-Y
13.05.2025
Albert David Standalone March 2025 Net Sales at Rs 74.89 crore, down 15.9% Y-o-Y
25.02.2026
Albert David Standalone December 2025 Net Sales at Rs 89.93 crore, up 8.24% Y-o-Y
13.11.2025
Albert David Standalone September 2025 Net Sales at Rs 87.24 crore, down 11.37% Y-o-Y
05.08.2025
Albert David Standalone June 2025 Net Sales at Rs 70.57 crore, down 21.03% Y-o-Y
13.05.2025
Albert David Standalone March 2025 Net Sales at Rs 74.89 crore, down 15.9% Y-o-Y
09.04.2026
08.04.2026
Indian CDMOs face tariff exposure via patented drug supply chains
08.04.2026
08.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth